Brokerages Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Target Price at $6.57

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has been assigned a consensus rating of "Buy" from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued a report on the stock in the last year is $6.57.

A number of analysts have weighed in on the stock. Needham & Company LLC reissued a "buy" rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Canaccord Genuity Group boosted their price target on shares of Taysha Gene Therapies from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Friday, May 16th. JMP Securities restated a "market outperform" rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Finally, Chardan Capital reiterated a "buy" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th.

Institutional Investors Weigh In On Taysha Gene Therapies

Several hedge funds have recently made changes to their positions in TSHA. Granahan Investment Management LLC raised its stake in Taysha Gene Therapies by 0.3% during the 1st quarter. Granahan Investment Management LLC now owns 1,640,793 shares of the company's stock valued at $2,281,000 after acquiring an additional 4,412 shares during the last quarter. Hsbc Holdings PLC increased its holdings in shares of Taysha Gene Therapies by 65.6% in the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock valued at $36,000 after purchasing an additional 8,076 shares during the period. Virtus ETF Advisers LLC raised its stake in shares of Taysha Gene Therapies by 43.0% during the fourth quarter. Virtus ETF Advisers LLC now owns 31,597 shares of the company's stock worth $55,000 after purchasing an additional 9,494 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Taysha Gene Therapies by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company's stock worth $6,182,000 after purchasing an additional 9,591 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Taysha Gene Therapies by 2.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock worth $820,000 after purchasing an additional 11,390 shares during the period. Institutional investors and hedge funds own 77.70% of the company's stock.

Taysha Gene Therapies Stock Down 5.1%

NASDAQ:TSHA traded down $0.14 during trading hours on Friday, hitting $2.61. The company's stock had a trading volume of 3,061,168 shares, compared to its average volume of 2,909,443. Taysha Gene Therapies has a 52-week low of $1.05 and a 52-week high of $4.32. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $560.27 million, a P/E ratio of 4.14 and a beta of 0.90. The stock has a fifty day moving average of $1.85 and a 200-day moving average of $1.88.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $2.30 million during the quarter, compared to analysts' expectations of $1.48 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. During the same period in the prior year, the firm posted ($0.10) EPS. On average, equities analysts forecast that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.